Supernus Pharmaceuticals (NASDAQ:SUPN) Lowered to Buy Rating by Wall Street Zen

Supernus Pharmaceuticals (NASDAQ:SUPN) was downgraded by equities research analysts at Wall Street Zen from a “strong-buy” rating to a “buy” rating in a research note issued on Saturday.

SUPN has been the topic of a number of other reports. Stifel Nicolaus raised their price target on Supernus Pharmaceuticals from $50.00 to $55.00 and gave the stock a “hold” rating in a research note on Friday, December 19th. Piper Sandler raised shares of Supernus Pharmaceuticals from a “neutral” rating to an “overweight” rating and raised their target price for the stock from $40.00 to $65.00 in a research report on Thursday, October 9th. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Supernus Pharmaceuticals in a research report on Monday, December 29th. Bank of America began coverage on shares of Supernus Pharmaceuticals in a research note on Wednesday, October 29th. They set a “buy” rating and a $65.00 price target on the stock. Finally, TD Cowen boosted their price objective on shares of Supernus Pharmaceuticals from $45.00 to $60.00 and gave the company a “buy” rating in a research note on Thursday, October 23rd. Four analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $61.60.

Supernus Pharmaceuticals Stock Performance

Shares of NASDAQ SUPN opened at $48.16 on Friday. The firm has a market cap of $2.76 billion, a P/E ratio of -141.64, a price-to-earnings-growth ratio of 0.52 and a beta of 0.67. Supernus Pharmaceuticals has a 1 year low of $29.16 and a 1 year high of $57.65. The firm’s 50 day moving average price is $48.76 and its 200 day moving average price is $46.10.

Supernus Pharmaceuticals (NASDAQ:SUPN) last issued its quarterly earnings results on Tuesday, November 4th. The specialty pharmaceutical company reported $0.46 earnings per share for the quarter, missing analysts’ consensus estimates of $0.82 by ($0.36). Supernus Pharmaceuticals had a positive return on equity of 11.51% and a negative net margin of 2.81%.The business had revenue of $170.00 million for the quarter, compared to analysts’ expectations of $175.82 million. During the same period in the prior year, the company earned $0.69 EPS. The company’s revenue for the quarter was up 9.3% compared to the same quarter last year. As a group, equities analysts predict that Supernus Pharmaceuticals will post 2.38 EPS for the current year.

Insiders Place Their Bets

In other Supernus Pharmaceuticals news, VP Padmanabh P. Bhatt sold 710 shares of the firm’s stock in a transaction dated Thursday, December 18th. The stock was sold at an average price of $44.44, for a total value of $31,552.40. Following the transaction, the vice president directly owned 14,508 shares of the company’s stock, valued at $644,735.52. This trade represents a 4.67% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, SVP Frank Mottola sold 20,000 shares of the business’s stock in a transaction dated Friday, December 19th. The stock was sold at an average price of $50.41, for a total value of $1,008,200.00. Following the transaction, the senior vice president owned 15,496 shares in the company, valued at approximately $781,153.36. This represents a 56.34% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Company insiders own 8.80% of the company’s stock.

Institutional Investors Weigh In On Supernus Pharmaceuticals

Several hedge funds have recently modified their holdings of the stock. Commonwealth of Pennsylvania Public School Empls Retrmt SYS boosted its holdings in Supernus Pharmaceuticals by 8.8% in the 2nd quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 14,375 shares of the specialty pharmaceutical company’s stock worth $453,000 after acquiring an additional 1,161 shares during the period. CWM LLC boosted its stake in shares of Supernus Pharmaceuticals by 92.4% in the second quarter. CWM LLC now owns 3,080 shares of the specialty pharmaceutical company’s stock valued at $97,000 after purchasing an additional 1,479 shares during the period. Meritage Portfolio Management boosted its stake in shares of Supernus Pharmaceuticals by 2.7% in the second quarter. Meritage Portfolio Management now owns 60,398 shares of the specialty pharmaceutical company’s stock valued at $1,904,000 after purchasing an additional 1,595 shares during the period. Castlekeep Investment Advisors LLC acquired a new stake in Supernus Pharmaceuticals during the 2nd quarter valued at $1,263,000. Finally, Universal Beteiligungs und Servicegesellschaft mbH increased its stake in Supernus Pharmaceuticals by 30.4% during the 2nd quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 85,534 shares of the specialty pharmaceutical company’s stock worth $2,696,000 after buying an additional 19,949 shares during the period.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained‐release formulations.

The company’s marketed portfolio includes Trokendi XR and Oxtellar XR, extended‐release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended‐release capsules), approved for the treatment of attention‐deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.